PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15116123-0 2004 Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1. Valproic Acid 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 102-106 15116123-2 2004 In this study, we have shown that valproic acid (VPA) (a histone deacetylase inhibitor) can inhibit the proliferation of both P-glycoprotein (P-gp)- and MDR-associated protein 1 (MRP1)-positive and -negative cells. Valproic Acid 34-47 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 15116123-2 2004 In this study, we have shown that valproic acid (VPA) (a histone deacetylase inhibitor) can inhibit the proliferation of both P-glycoprotein (P-gp)- and MDR-associated protein 1 (MRP1)-positive and -negative cells. Valproic Acid 49-52 ATP binding cassette subfamily B member 1 Homo sapiens 126-140 15116123-3 2004 VPA also induced apoptosis of P-gp-positive cells. Valproic Acid 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 30-34 15116123-8 2004 VPA also induced apoptosis in AML patient cells expressing P-gp and/or MRP1. Valproic Acid 0-3 ATP binding cassette subfamily B member 1 Homo sapiens 59-63 32054883-7 2020 Investigation of the effect of VA upon the brain endothelial cells (hCMEC/D3) in hyperexcitatory conditions confirmed suppression of COX-2-dependent P-gp upregulation by VA. Valproic Acid 31-33 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 12954800-8 2003 In this assay, also phenytoin, lamotrigine, and valproate revealed Pgp inhibitory potency. Valproic Acid 48-57 ATP binding cassette subfamily B member 1 Homo sapiens 67-70 32054883-7 2020 Investigation of the effect of VA upon the brain endothelial cells (hCMEC/D3) in hyperexcitatory conditions confirmed suppression of COX-2-dependent P-gp upregulation by VA. Valproic Acid 170-172 ATP binding cassette subfamily B member 1 Homo sapiens 149-153 28961159-4 2017 phenytoin, carbamazepine, valproate, lamotrigine, topiramate and levetiracetam, on the expression and function of ABCB1, ABCC1, ABCC2 and ABCG2 in Caco2 and HepG2 cell lines through real time PCR, western blot and functional activity assays. Valproic Acid 26-35 ATP binding cassette subfamily B member 1 Homo sapiens 114-119 30963442-5 2019 Of the HDAC inhibitors profiled, valproic acid (VPA), apicidin, and suberoylanilide hydroxamic acid (SAHA) increased MDR1 mRNA and protein levels by 30-200%, which corresponded with reduced intracellular accumulation of the MDR1 substrate rhodamine 123. Valproic Acid 33-46 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 30963442-5 2019 Of the HDAC inhibitors profiled, valproic acid (VPA), apicidin, and suberoylanilide hydroxamic acid (SAHA) increased MDR1 mRNA and protein levels by 30-200%, which corresponded with reduced intracellular accumulation of the MDR1 substrate rhodamine 123. Valproic Acid 33-46 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 30963442-5 2019 Of the HDAC inhibitors profiled, valproic acid (VPA), apicidin, and suberoylanilide hydroxamic acid (SAHA) increased MDR1 mRNA and protein levels by 30-200%, which corresponded with reduced intracellular accumulation of the MDR1 substrate rhodamine 123. Valproic Acid 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 30963442-5 2019 Of the HDAC inhibitors profiled, valproic acid (VPA), apicidin, and suberoylanilide hydroxamic acid (SAHA) increased MDR1 mRNA and protein levels by 30-200%, which corresponded with reduced intracellular accumulation of the MDR1 substrate rhodamine 123. Valproic Acid 48-51 ATP binding cassette subfamily B member 1 Homo sapiens 224-228 28961159-7 2017 Valproate caused a significant increase in the expression and functional activity of ABCB1 in HepG2 only. Valproic Acid 0-9 ATP binding cassette subfamily B member 1 Homo sapiens 85-90 21316268-7 2011 The aim of this study was to assess the association of ABCB1 and PXR genetic polymorphisms with response to the carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in epilepsy. Valproic Acid 135-151 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 27450623-6 2016 Carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid might decrease the effect of NOACs by inducing P-glycoprotein (P-gp) activity. Valproic Acid 59-72 ATP binding cassette subfamily B member 1 Homo sapiens 120-134 27450623-6 2016 Carbamazepine, levetiracetam, phenobarbital, phenytoin and valproic acid might decrease the effect of NOACs by inducing P-glycoprotein (P-gp) activity. Valproic Acid 59-72 ATP binding cassette subfamily B member 1 Homo sapiens 136-140 24477677-11 2014 Of the various AEDs examined, only carbamazepine (100 muM) moderately increased Pgp functionality in hCMEC/D3, while valproate (300 muM) inhibited Pgp. Valproic Acid 117-126 ATP binding cassette subfamily B member 1 Homo sapiens 147-150 21530324-4 2011 The purpose of this study was to investigate a possible link between ABCB1 rs3789243 C>T, C1236T, G2677T/A, rs6949448 C>T, and C3435T haplotypes with response to carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in Malaysian epilepsy patients. Valproic Acid 191-207 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 21530324-4 2011 The purpose of this study was to investigate a possible link between ABCB1 rs3789243 C>T, C1236T, G2677T/A, rs6949448 C>T, and C3435T haplotypes with response to carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in Malaysian epilepsy patients. Valproic Acid 209-212 ATP binding cassette subfamily B member 1 Homo sapiens 69-74 21316268-7 2011 The aim of this study was to assess the association of ABCB1 and PXR genetic polymorphisms with response to the carbamazepine (CBZ) or sodium valproate (VPA) monotherapy in epilepsy. Valproic Acid 153-156 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 21388909-0 2011 Association between ABCB1 polymorphism and response to sodium valproate treatment in Malaysian epilepsy patients. Valproic Acid 55-71 ATP binding cassette subfamily B member 1 Homo sapiens 20-25 21388909-2 2011 Here, we investigated the possible association between ABCB1 polymorphisms and sodium valproate (VPA) treatment in Malaysian epilepsy patients. Valproic Acid 79-95 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 21388909-2 2011 Here, we investigated the possible association between ABCB1 polymorphisms and sodium valproate (VPA) treatment in Malaysian epilepsy patients. Valproic Acid 97-100 ATP binding cassette subfamily B member 1 Homo sapiens 55-60 17392393-0 2007 Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Valproic Acid 0-13 ATP binding cassette subfamily B member 1 Homo sapiens 33-37 20417680-3 2010 The aim of the present study was to investigate the role of ABCB1 polymorphisms: C1236T, G2677T/A and C3435T in determining drug response to first line antiepileptic drugs (AEDs) namely phenobarbitone, phenytoin, carbamazepine and valproate in North Indian cohort of epilepsy patients. Valproic Acid 231-240 ATP binding cassette subfamily B member 1 Homo sapiens 60-65 19458058-9 2009 Chromatin immunoprecipitation revealed the hyperacetylation of histone proteins in the promoter regions of MDR1, BCRP, and MRP8 on valproate treatment. Valproic Acid 131-140 ATP binding cassette subfamily B member 1 Homo sapiens 107-111 18165917-0 2009 Association of MDR1 C3435T polymorphism with bipolar disorder in patients treated with valproic acid. Valproic Acid 87-100 ATP binding cassette subfamily B member 1 Homo sapiens 15-19 18165917-4 2009 We investigated the association of exon 26 C3435T genetic variants of MDR1 gene with susceptibility to bipolar disorder and serum valproic acid concentration. Valproic Acid 130-143 ATP binding cassette subfamily B member 1 Homo sapiens 70-74 17671692-0 2007 The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Valproic Acid 79-92 ATP binding cassette subfamily B member 1 Homo sapiens 117-121 17392393-1 2007 In our study, we tested the hypothesis whether valproic acid (VPA) in therapeutic concentrations has potential to affect expression of CYP3A4 and MDR1 via constitutive androstane receptor (CAR) and pregnane X receptor (PXR) pathways. Valproic Acid 47-60 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 17392393-1 2007 In our study, we tested the hypothesis whether valproic acid (VPA) in therapeutic concentrations has potential to affect expression of CYP3A4 and MDR1 via constitutive androstane receptor (CAR) and pregnane X receptor (PXR) pathways. Valproic Acid 62-65 ATP binding cassette subfamily B member 1 Homo sapiens 146-150 16894351-0 2006 The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Valproic Acid 40-53 ATP binding cassette subfamily B member 1 Homo sapiens 63-77 16894351-10 2006 The effect of a series of valproic acid derivatives on P-gp expression in SW620 and KG1a cells correlated with their HDAC inhibition potencies. Valproic Acid 26-39 ATP binding cassette subfamily B member 1 Homo sapiens 55-59 16894351-13 2006 CONCLUSIONS: Valproic acid increased P-gp expression and function in human tumour cell lines and in rat liver. Valproic Acid 13-26 ATP binding cassette subfamily B member 1 Homo sapiens 37-41